# Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease

> **NCT03893240** · NA · COMPLETED · sponsor: **Spark Therapeutics, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Pompe Disease
- Pompe Disease (Late-onset)
- Glycogen Storage Disease Type 2
- LOPD
- Lysosomal Storage Diseases
- Acid Maltase Deficiency

## Interventions

- **DIAGNOSTIC_TEST:** Neutralizing Antibody to SPK-3006 capsid

## Key facts

- **NCT ID:** NCT03893240
- **Lead sponsor:** Spark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2020-10-27
- **Final completion:** 2020-10-27
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03893240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03893240, "Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03893240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*